Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

Inclusion Criteria: * The subjects voluntarily participated in the study and agreed to sign the written informed consent. They had good compliance and cooperated with the follow-up * Be at least 18 years old at the time of signing the informed consent form, with no gender restrictions. * Hepatocellular carcinoma diagnosed by histology or imaging * At least one measurable lesion (according to the requirements of RECIST version 1.1, the long diameter of the measurable lesion on spiral CT scan is ≥10mm or the short diameter of the enlarged lymph node is ≥15mm) * No systematic treatment has been received before * CNLC：Ib to IIIa * There is at least one of the following high-risk factors for postoperative recurrence: AFP\>400ng/ml; Single tumor \>5cm; The number of tumors is greater than 3 or any one of them is greater than 3cm; There are vascular tumor thrombus or tumors adjacent to large blood vessels, etc. * The ECOG score was 0-1 within one week before enrollment * Hematology and organ functions are adequate * Fertile women: Agree to abstain from sex (avoid heterosexual intercourse) or use contraceptive methods with an annual contraceptive failure rate of less than 1% during the treatment period and for at least 6 months after the last administration Exclusion Criteria: * Have received any systemic treatment * ECOG score \>1 * Definite extrahepatic metastasis * Pregnant women (with a positive pregnancy test before taking the medicine) or lactating women * Those who are know…